Drug Resistance

Part of the Cancer Treatment and Research book series (CTAR, volume 154)


Elucidation of a stem-cell origin of cancers and drug resistance may steer us away from many well-intentioned but potentially futile treatments.


Drug Resistance Cancer Stem Cell Embryonal Carcinoma Gompertzian Model Distant Metastasis Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance [review]. Nat Rev Cancer 5:275–284CrossRefPubMedGoogle Scholar
  2. 2.
    Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93:1075–1085PubMedGoogle Scholar
  3. 3.
    Pallis M, Russell N (2000) P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 95:2897–2904PubMedGoogle Scholar
  4. 4.
    Baer MR, George SL, Dodge RK et al (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224–1232PubMedGoogle Scholar
  5. 5.
    Greenberg PL, Lee SJ, Advani R et al (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22:1078–1086, Erratum in J Clin Oncol 2004;22(13):2747CrossRefPubMedGoogle Scholar
  6. 6.
    Zhou S, Schuetz JD, Bunting KD et al (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028–1034CrossRefPubMedGoogle Scholar
  7. 7.
    Good JR, Kuspa A (2000) Evidence that a cell-type-specific efflux pump regulates cell differentiation in Dictyostelium. Dev Biol 220:53–61CrossRefPubMedGoogle Scholar
  8. 8.
    Osawa M, Hanada K, Hamada H et al (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273:242–245CrossRefPubMedGoogle Scholar
  9. 9.
    Gussoni E, Soneoka Y, Strickland CD et al (1999) Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401:390–394PubMedGoogle Scholar
  10. 10.
    Jackson KA, Mi T, Goodell MA (1999) Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA 96:14482–14486CrossRefPubMedGoogle Scholar
  11. 11.
    Hulspas R, Quesenberry PJ (2000) Characterization of neurosphere cell phenotypes by flow cytometry. Cytometry 40:245–250CrossRefPubMedGoogle Scholar
  12. 12.
    Cervantes RB, Stringer JR, Shao C et al (2002) Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc Natl Acad Sci USA 99:3586–3590CrossRefPubMedGoogle Scholar
  13. 13.
    Myllyperkiö MH, Vilpo JA (1999) Increased DNA single-strand break joining activity in UV-irradiated CD34+ versus CD34− bone marrow cells. Mutat Res 425:169–176PubMedGoogle Scholar
  14. 14.
    Ellis HM, Horvitz HR (1986) Genetic control of programmed cell death in the nematode C. elegans. Cell 44:817–829CrossRefPubMedGoogle Scholar
  15. 15.
    McDonnell TJ, Deane N, Platt FM et al (1989) bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79–88CrossRefPubMedGoogle Scholar
  16. 16.
    Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440–442CrossRefPubMedGoogle Scholar
  17. 17.
    Tu S-M, Lopez A, Leibovici D et al (2009) Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 115:2872–2880CrossRefPubMedGoogle Scholar
  18. 18.
    Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63(11–12):1727–1733PubMedGoogle Scholar
  19. 19.
    Laird AK (1969) Dynamics of growth in tumors and in normal organisms. Natl Cancer Inst Monogr 30:15–28PubMedGoogle Scholar
  20. 20.
    Williams SD, Stablein DM, Einhorn LH et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433–1438CrossRefPubMedGoogle Scholar
  21. 21.
    Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542–547CrossRefPubMedGoogle Scholar
  22. 22.
    Fisher RI, DeVita VT, Hubbard SP et al (1979) Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–763PubMedGoogle Scholar
  23. 23.
    Kardinal CG, Perry MC, Korzun AH et al (1988) Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB study 8081. Cancer 61:415–419CrossRefPubMedGoogle Scholar
  24. 24.
    Adair F, Berg J, Joubert L et al (1974) Long-term followup of breast cancer patients: the 30-year report. Cancer 33:1145–1150CrossRefPubMedGoogle Scholar
  25. 25.
    Ferguson DJ, Meier P, Karrison T et al (1982) Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. JAMA 248:1337–1341CrossRefPubMedGoogle Scholar
  26. 26.
    Brinkley D, Haybrittle JL (1975) The curability of breast cancer. Lancet 2:95–97CrossRefPubMedGoogle Scholar
  27. 27.
    Rutqvist LE, Wallgren A, Nilsson B (1984) Is breast cancer a curable disease? A study of 14,731 women with breast cancer from the Cancer Registry of Norway. Cancer 53:1793–1800CrossRefPubMedGoogle Scholar
  28. 28.
    Fisher B, Redmond C, Poisson R et al (1989) Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320:822–828, Erratum in N Engl J Med 1994;330(20):1467CrossRefPubMedGoogle Scholar
  29. 29.
    Balch CM, Soong S-J, Bartolucci AA et al (1996) Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255–266CrossRefPubMedGoogle Scholar
  30. 30.
    Leighton C, Fisher B, Bauman G et al (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294–1301PubMedGoogle Scholar
  31. 31.
    Le Cesne A, Judson I, Crowther D et al (2000) Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2676–2684PubMedGoogle Scholar
  32. 32.
    Peters WP, Rosner GL, Vredenburgh JJ et al (2005) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23:2191–2200CrossRefPubMedGoogle Scholar
  33. 33.
    Sternberg CN, de Mulder PHM, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924. J Clin Oncol 19:2638–2646PubMedGoogle Scholar
  34. 34.
    Giaccone G, Dalesio O, McVie GJ et al; European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (1993) Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 11:1230–1240PubMedGoogle Scholar
  35. 35.
    Markman M, Liu PY, Wilczynski S et al (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460–2465CrossRefPubMedGoogle Scholar
  36. 36.
    Muss HB, Case LD, Richards F 2nd et al (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325:1342–1348CrossRefPubMedGoogle Scholar
  37. 37.
    Chapman PB, Einhorn LH, Meyers ML et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745–2751PubMedGoogle Scholar
  38. 38.
    Thigpen JT, Brady MF, Homesley HD et al (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22:3902–3908CrossRefPubMedGoogle Scholar
  39. 39.
    Santoro A, Tursz T, Mouridsen H et al (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537–1545PubMedGoogle Scholar
  40. 40.
    Ohtsu A, Shimada Y, Shirao K et al (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54–59CrossRefPubMedGoogle Scholar
  41. 41.
    Niell HV, Herndon JE II, Miller AA et al (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23:3752–3759CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.The University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations